SALINAZID

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H11N3O2
Molecular Weight	241.2453
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OC1=C(\C=N\NC(=O)C2=CC=NC=C2)C=CC=C1

InChI

InChIKey=VBIZUNYMJSPHBH-OQLLNIDSSA-N

InChI=1S/C13H11N3O2/c17-12-4-2-1-3-11(12)9-15-16-13(18)10-5-7-14-8-6-10/h1-9,17H,(H,16,18)/b15-9+

HIDE SMILES / InChI

Molecular Formula	C13H11N3O2
Molecular Weight	241.2453
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	1
Optical Activity	NONE

Description
Sources: http://www.drugfuture.com/chemdata/salinazid.html | http://www.reference.md/files/C049/mC049137.html

Salinazid (Acozid, Nupasal-213) is an antibacterial agent used primarily as a tuberculostatic. It used to be the treatment of choice for tuberculosis.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Mycobacterium tuberculosis H37Rv 11 Target ID: CHEMBL2111188 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13278849	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Tuberculosis 83 Sources: https://www.ncbi.nlm.nih.gov/pubmed/14386367 https://www.ncbi.nlm.nih.gov/pubmed/13446417	Primary		Approved 8429	Acozid Approved Use Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis.

PubMed

Title	Date	PubMed
The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro.	2004	15588138
Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease.	2009 Oct 16	19679656
Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action.	2012 May 30	22521999

Patents

Sample Use Guides

In Vivo Use Guide

In the therapeutic trial the drugs were given to a test group in the dose of' 200 mg of INAH plus 1600 mg of Salinazid (Nupasal-213) daily. Two tablets each containing 50 mg INAH and 400 mg Nupasal-213 were given twice daily. A dose of Nupasal-213 of 1500 mg daily is well tolerated by patients not receiving INAH.

Route of Administration: Oral

In Vitro Use Guide

In vitro, the minimum inhibitory concentration (MIC) of Salinazid was 0.09 ug/ml

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:20:30 GMT 2023` Edited by `admin` on `Fri Dec 15 15:20:30 GMT 2023`
Record UNII	2H42W1O4O2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

SALINAZID

Official Name

English

SALINAZID [MI]

Common Name

English

SALIZID

Common Name

English

Salinazid [WHO-DD]

Common Name

English

salinazid [INN]

Common Name

English

NSC-33760

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C280